• Mon. Nov 30th, 2020

Pharma Oracle

Evolving Today for better Tomorrow

Long lasting Perfomance: Lannett Company, Inc. (NYSE: LCI)

On 21 Feb 2020, Lannett Company, Inc. (NYSE: LCI) spotted trading -41.11% off 52-week high price. On the other end, the stock has been noted 77.30% away from the low price over the last 52-weeks. The stock changed -2.25% to recent value of $9.14. The stock transacted 597966 shares during most recent day however it has an average volume of 877.9K shares. The company has 41.27M of outstanding shares and 31.37M shares were floated in the market.

Lannett Company, Inc. (LCI) recently stated financial results for its fiscal 2020 second quarter ended December 31, 2019.

“For our fiscal 2020 second quarter, strong sales across multiple product categories drove solid increases to our net sales and net income over our fiscal 2020 first-quarter results,” stated Tim Crew, chief executive officer of Lannett.  “Our improved topline was due in part to the introduction of seven new products in the second quarter of fiscal 2020, as well as a full quarter of sales of Posaconazole.  We plan to commence marketing an additional 10 or so products in the second half of the year, including Numbrino®, our recently approved, branded topical anesthetic product.

For the fiscal 2020 second quarter on a GAAP basis, net sales were $136.1M contrast with $193.7M for the second quarter of fiscal 2019.  Gross profit was $41.3M, or 30% of net sales, contrast with $69.8M, or 36% of net sales.  Net income was $5.1M, or $0.13 per diluted share, contrast with $12.4M, or $0.32 per diluted share.

For the fiscal 2020 second quarter stated on a Non-GAAP basis, net sales were $136.1M contrast with $193.7M for the second quarter of fiscal 2019.  Adjusted gross profit was $50.2M, or 37% of net sales, contrast with $86.0M, or 44% of net sales, for the prior-year second quarter.  Adjusted interest expense was $13.1M contrast with $17.1M for the second quarter of fiscal 2019.  Adjusted net income was $11.7M, or $0.27 per diluted share, contrast with $33.6M, or $0.86 per diluted share, for the fiscal 2019 second quarter.  Adjusted EBITDA for the fiscal 2020 second quarter was $35.8M.

Its earnings per share (EPS) expected to touch remained -839.10% for this year while earning per share for the next 5-years is expected to reach at 15.00%. LCI has a gross margin of 34.80% and an operating margin of 11.60% while its profit margin remained -0.70% for the last 12 months. According to the most recent quarter its current ratio was 2 that represents company’s ability to meet its current financial obligations. The price moved ahead of 2.85% from the mean of 20 days, 2.64% from mean of 50 days SMA and performed 6.38% from mean of 200 days price. Company’s performance for the week was 2.01%, -4.89% for month and YTD performance remained 3.63%.

 

Leave a Reply

Your email address will not be published. Required fields are marked *